Current Treatment Options for Advanced or Metastatic Melanoma
Until recently, there was a dearth of effective treatments for surgically unresectable or metastatic melanoma. At best, cytotoxic chemotherapy such as dacarbazine yields a response rate of approximately ten percent. Similar response rates are seen with immunotherapies, such as interleukin-2 (IL-2), but these responses may be extremely durable. Neither chemotherapy nor IL-2 clearly results in improved overall survival (OS), however .
The outlook for patients with advanced melanoma significantly brightened with the identification of specific BRAF and MEK inhibitors and immune modulating antibodies as effective therapies for this disease. Ipilimumab, a cytotoxic T-lymphocyte antigen (CTLA4) blocking antibody, was approved for treatment of metastatic melanoma. Responses to ipilimumab are on the order of 10-15%. Unlike the afore-mentioned agents, ipilimumab does improve median OS compared to the control arms in randomized clinical trials . In September 2014, the programmed death-1 (PD-1) blocking antibody pembrolizumab (MK-3475, Merck) was FDA-approved for metastatic melanoma that has progressed on ipilimumab and BRAF inhibitors (if BRAF mutated).
Pembrolizumab has an overall response rate (ORR) of 24% with many of these responses ongoing for six months or longer . In all, there have been 6 FDA-approved therapies for the treatment of patients with metastatic melanoma since 2011.
High response rates for BRAF V600 mutant metastatic melanoma are seen with as the type 1 BRAF inhibitors vemurafenib (formerly PLX4032) and dabrafenib (formerly GSK2118436) .
Unfortunately, though initial responses to these agents are impressive, progression free (PFS) is on the order of 6-7 months. Combining BRAF inhibition with MEK inhibition results in improved PFS compared to BRAF inhibition alone . However, not all melanomas express the mutated BRAF protein, and not all melanomas with mutant BRAF are responsive to these targeted therapies. Thus, effective therapies that address both de novo and acquired resistance to BRAF and MEK inhibitors remain a subject of active research. Understanding the biology of melanoma will be key in identifying strategies to address resistance to therapy.
Targeting the MAPK pathway in melanoma
BRAF is a serine-threonine protein kinase belonging to the RAF family of kinases, which is part of the MAPK signaling pathway. Under normal signaling conditions, binding of a growth factor to a RTK such as c-KIT activates RAS which then activates the RAF kinases. There are 3 identified RAF kinases: ARAF, BRAF and CRAF. RAF activation in turn phosphorylates MEK, leading to activation of ERK and subsequent phosphorylation of various targets that result in cell proliferation and other key biologic processes (Fig. 1) , median PFS was 6.3 months and median OS was 13.1 months, while it was 4.5 months and 12.9 months, respectively, for those with BRAF
V600K
. Furthermore, BREAK-3, the phase III study comparing dabrafenib to dacarbazine for first-line treatment of advanced melanoma randomized 250 patients 3:1 to receive either dabrafenib or dacarbazine. The primary end point was investigator-assessed PFS. Consistent with the Phase I data, the response rate was 52%, (95% CI 45-59) for the dabrafenib arm and 17% (95% CI 9-29) for the dacarbazine arm. There was a 3% complete response rate among patients who received dabrafenib. The median PFS was 5·1 months for dabrafenib and 2·7 months for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001) . Given Both vemurafenib and dabrafenib are generally well-tolerated. With vemurafenib, adverse events were mainly grade 2 or 3 in severity and included 18% incidence of cutaneous events (squamous cell carcinoma, keratoacanthoma, or both) managed by excision, arthralgia (21%), fatigue (13%), and 12% incidence of photosensitivity skin reactions, the most severe of which could be prevented by the use of sunblock. Adverse reactions requiring dose modifications or interruptions occurred in 38% of patients . For dabrafenib, adverse events reported in the phase I study included skin changes, low grade cutaneous SCC, headache, nausea, fatigue, and vomiting . In BREAK-2, rates of the most common AEs were: arthralgia (33%), hyperkeratosis (27%), and pyrexia (24%). Twenty-five patients (27%) had a serious AE and nine (10%) had squamous cell carcinoma. In the Phase III study, 53% of patients developed adverse events compared to 44% in the dacarbazine arm. These include hyperkeratosis, palmar-plantar erythrodysesthesia syndrome, headache, pyrexia, arthralgia, papilloma, and alopecia. Grade 3 or 4 adverse events were uncommon in either group .
Limitations of BRAF Inhibitors
Only melanoma cells with mutated BRAF are susceptible to inhibition by type I Raf inhibitors. This is hypothesized to be because mutant BRAF is locked in an activated conformational state, which selectively allows inhibitor binding at lower concentrations than needed for inhibition of wild-type BRAF . Constitutive activation of BRAF V600E may also obviate the need for binding 
